Oncology Central

The future of melanoma therapy: developing new drugs and improving the use of old ones

0

The treatment of metastatic melanomas is one of the most interesting and exciting fields in oncology. In fact, worldwide, seven drugs, including three therapeutic immune checkpoint inhibitors and four BRAF-MEK blockers, have been approved for use since 2011. The interaction between the immune system and the melanoma has always been one of the peculiarities of this disease. The first attempt to develop a treatment that could improve the immunological activity against melanoma, through IL-2, provided encouraging results in terms of activity; however, the associated toxicity immediately discouraged routine use. In 2010, the advent of ipilimumab, an anti-CTLA-4 inhibitor, changed the whole scenario.

To view restricted content, please:
.

Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.